The mean change in PSA level was defined as the primary outcome measure. The post-treatment differences between the intervention and the control groups were evaluated descriptively. The protocol stipulated that ha tag a formal meta-analysis would be performed if methodological, clinical and statistical homogeneity allowed.
3. Results
The searches generated 64740 hits, of which 8 RCTs met the inclusion criteria. Fig. 1 illustrates the process of screening and selecting RCTs. The key data from the included RCTs are summarised in Table 1, and Table 2 presents the lymphatic system details of the treatment regimens from each RCT.
Full-size image (31 K)
Fig. 1.
Flow chart diagram of eligibility criteria.
Figure options
Table 1.
Double blind, placebo-controlled RCTs of dietary supplements for PC treatment.
First author (year)(origin) [ref] Sample size/type of cancer Interventions (Regimen) Gleason score/PSA levelsb Main results/intergroup difference Author's conclusion Follow-up Adverse effects COIa Risk of biasc
View User's Journal
Results show important individual variations both in terms
 |
